In patients with cryptogenic stroke and evidence of atrial cardiopathy without atrial fibrillation, apixaban did not reduce recurrent stroke vs aspirin in the ARCADIA trial.
Late tenecteplase treatment (4.5-24 hours post-stroke) did not benefit patients with large-vessel occlusion stroke, but could help those with M1 occlusions, a new study showed.
The STOP-CAD study signaled a short course of an antithrombotic regimen might lower ischemic stroke risk in some patients without significantly increasing major bleeding.
Adding low-dose methylprednisolone to stroke thrombectomy did not improve overall disability, but there were other possible benefits seen in the MARVEL trial.